CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.
Advani R. et al, (2018), N Engl J Med, 379, 1711 - 1721
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
Trotman J. et al, (2018), Lancet Oncol, 19, 1530 - 1542
Comparison of the measurement properties of paper and electronic version of HM-PRO, a new patient-reported outcome measure for use in patients with haematological malignancies: an equivalence study
Goswami P. et al, (2018), QUALITY OF LIFE RESEARCH, 27, S138 - S139
Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries.
Collins GP. et al, (2018), Leuk Lymphoma, 59, 2113 - 2120
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
Hiddemann W. et al, (2018), J Clin Oncol, 36, 2395 - 2404
Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS).
Chen RW. et al, (2018), JOURNAL OF CLINICAL ONCOLOGY, 36
Improving outcomes with brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma.
Straus DJ. et al, (2018), JOURNAL OF CLINICAL ONCOLOGY, 36
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
Armand P. et al, (2018), J Clin Oncol, 36, 1428 - 1439
CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial.
Gleeson M. et al, (2018), Lancet Haematol, 5, e190 - e200
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
Roemer MGM. et al, (2018), J Clin Oncol, 36, 942 - 950
Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma From the Phase 2 CheckMate 205 Study
Cohen JB. et al, (2018), BRITISH JOURNAL OF HAEMATOLOGY, 181, 87 - 88
Seronegative antibody-mediated neurology after immune checkpoint inhibitors
Wilson R. et al, (2018), Annals of Clinical and Translational Neurology
Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting (vol 179, pg 471, 2017)
Eyre TA. et al, (2018), BRITISH JOURNAL OF HAEMATOLOGY, 180, 309 - 309
The cost-effectiveness of immediate treatment or watch and wait with deferred chemotherapy for advanced asymptomatic follicular lymphoma.
Prettyjohns M. et al, (2018), Br J Haematol, 180, 52 - 59
Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting.
Eyre TA. et al, (2017), British journal of haematology, 179, 471 - 479
Development of HM-PRO, a haematology specific Patient-Reported Outcome Measure: content validation
Goswami P. et al, (2017), QUALITY OF LIFE RESEARCH, 26, 130 - 130